Pharmacokinetic modeling of [18F]fluorodeoxyglucose (FDG) for premature infants, and newborns through 5-year-olds

Khamwan, Kitiwat; Plyku, Donika; O’Reilly, Shannon E.; Goodkind, Alison; Cao, Xinhua; Fahey, Frederic H.; Treves, S. Ted; Bolch, Wesley E.; Sgouros, George

doi:10.1186/s13550-016-0179-6

EJNMMI Research

Table 1 Patients’ characteristic data

From: Pharmacokinetic modeling of [¹⁸F]fluorodeoxyglucose (FDG) for premature infants, and newborns through 5-year-olds

Patient	Sex	Age (months)	Weight (kg)	Activity (MBq)	Acquisition time after injection (min)	Provisional/suspected diagnosis (reason for PET/CT examination)
1	F	11	8.3	51.8	93	Rhabdomyosarcoma^a
2	F	16	10.4	57.3	83	Neurofibromatosis 1 (abdominal/right flank pain)
3	F	3	4.5	27.1	94	Ewing’s sarcoma^b
4	F	4	7.3	38.4	79	Suspected pelvic carcinoma
5	F	10	5.9	31.0	69	Retroperitoneal sarcoma s/p chemotherapy (assess for tumor activity)
6	F	3	4.0	25.9	60	Infantile adenocarcinoma^b
7	F	0.5	3.1	19.6	60	Infantile myofibromatosis^a
8	F	16	11.6	64.0	84	Rhabdomyosarcoma^a
9	M	6	10.0	58.8	126	Suspected left scalp Ewing’s sarcoma
10	M	9	7.7	44.4	97	Suspected pheochromocytoma^a
11	M	8	9.6	50.0	125	Suspected malignant liver lesion^b
12	F	36	12.4	80.3	74	Rhabdomyosarcoma s/p therapy^a
13	F	36	12.0	69.5	86	Rhabdomyosarcoma s/p therapy^b
14	F	36	11.6	64.0	71	Rhabdomyosarcoma s/p therapy^b
15	F	12	9.1	51.0	66	Infantile fibrosarcoma of pelvis s/p therapy^a
16	M	60	18.0	64.2	70	Diffuse large B cell lymphoma stage IV^a
17	M	7	8.6	30.6	78	Hodgkin’s lymphoma s/p chemotherapy^a
18	F	48	16.0	91.2	81	Localized Ewing’s sarcoma^a
19	M	48	15.1	82.9	73	Neurofibromatosis 1 (tumor activity evaluation)
20	F	13	7.3	40.7	60	Suspected malignant pelvic mass^b
21	M	24	12.4	81.2	85	High-risk neuroblastoma s/p therapy^a
22	M	9	10.5	94.8	113	Multifocal inflammatory myofibroblastic tumor of the lungs s/p chemotherapy^a
23	F	10	9.9	58.8	109	B cell lymphoma^a
24	F	7	8.1	48.1	117	Anaplastic large-cell lymphoma s/p therapy^a
25	F	11	7.0	37.4	88	Hepatoblastoma s/p chemotherapy^a
26	F	11	10.5	57.1	106	Suspected left renal cell carcinoma^a
27	M	23	12.6	79.1	89	Suspected rhabdomyosarcoma
28	M	24	12.7	75.6	69	Right calf alveolar rhabdomyosarcoma^a
29	M	36	13.8	81.4	117	Stage IV neuroblastoma s/p therapy^a
30	M	36	14.3	74.0	83	Stage IV neuroblastoma s/p therapy^a
31	M	48	21.7	121.4	82	Rhabdomyosarcoma^a
32	M	60	22.0	125.8	119	Spinal neurofibroma^a
33	F	60	20.1	116.6	81	Suspected neck LN in thyroid cancer^b
34	M	60	16.6	92.9	83	Metastatic glomus tumor^a
35	M	60	16.8	96.9	75	Malignant rhabdoid tumor s/p therapy^a

^aEvaluation for staging and/or response (post therapy)
^bEvaluation for metastasis

Back to article page